- Home
- NGNE vs USCB Comparison
NGNE vs USCB Comparison
Compare NGNE & USCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- USCB
- Stock Information
- Founded
- NGNE 2003
- USCB 2002
- Country
- NGNE United States
- USCB United States
- Employees
- NGNE N/A
- USCB N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- USCB Major Banks
- Sector
- NGNE Health Care
- USCB Finance
- Exchange
- NGNE Nasdaq
- USCB Nasdaq
- Market Cap
- NGNE 325.3M
- USCB 316.4M
- IPO Year
- NGNE N/A
- USCB 2021
- Fundamental
- Price
- NGNE $18.48
- USCB $17.34
- Analyst Decision
- NGNE Strong Buy
- USCB Buy
- Analyst Count
- NGNE 7
- USCB 3
- Target Price
- NGNE $41.86
- USCB $20.33
- AVG Volume (30 Days)
- NGNE 110.1K
- USCB 16.8K
- Earning Date
- NGNE 08-11-2025
- USCB 07-24-2025
- Dividend Yield
- NGNE N/A
- USCB 2.30%
- EPS Growth
- NGNE N/A
- USCB 67.08
- EPS
- NGNE N/A
- USCB 1.47
- Revenue
- NGNE N/A
- USCB $88,094,000.00
- Revenue This Year
- NGNE N/A
- USCB $26.38
- Revenue Next Year
- NGNE N/A
- USCB $4.39
- P/E Ratio
- NGNE N/A
- USCB $11.83
- Revenue Growth
- NGNE N/A
- USCB 32.06
- 52 Week Low
- NGNE $6.88
- USCB $13.85
- 52 Week High
- NGNE $74.49
- USCB $21.86
- Technical
- Relative Strength Index (RSI)
- NGNE 35.93
- USCB 55.15
- Support Level
- NGNE $19.59
- USCB $17.10
- Resistance Level
- NGNE $20.46
- USCB $17.98
- Average True Range (ATR)
- NGNE 1.23
- USCB 0.52
- MACD
- NGNE -0.20
- USCB 0.06
- Stochastic Oscillator
- NGNE 13.37
- USCB 73.38
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About USCB USCB Financial Holdings Inc.
USCB Financial Holdings Inc is a community bank. Through its network of branches and its online banking platform, it offers customers a wide range of financial products and services such as Personal and Business Checking, Savings, Credit Cards, and Real Estate Loans.